These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21077963)

  • 1. Unexpected enlargement of clinically silent pituitary gonadotroph adenoma induced by goserelin acetate given as treatment for prostate cancer.
    Ito Y
    Int J Urol; 2011 Jan; 18(1):83-4. PubMed ID: 21077963
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis.
    Sahli R; Christ E; Kuhlen D; Giger O; Vajtai I
    Pituitary; 2011 Dec; 14(4):405-8. PubMed ID: 19760170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
    N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K; Berger M; Ball R
    J Urol; 1998 Aug; 160(2):497-8. PubMed ID: 9679910
    [No Abstract]   [Full Text] [Related]  

  • 6. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
    Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
    Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of local cooling at injection site of goserelin acetate for pain relief].
    Nukui A; Morita T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):967-72. PubMed ID: 21677488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness.
    Eaton HJ; Phillips PJ; Hanieh A; Cooper J; Bolt J; Torpy DJ
    Intern Med J; 2001 Jul; 31(5):313-4. PubMed ID: 11512605
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goserelin-induced depression in a man with prostate cancer.
    Ahmadi-Davis S; Velasco R; Stewart JT
    Psychosomatics; 2014; 55(6):720-2. PubMed ID: 24629897
    [No Abstract]   [Full Text] [Related]  

  • 14. [Zoladex (ICI) in the therapy of prostatic cancer patients].
    Popko AS; Dokshin KL
    Urol Nefrol (Mosk); 1996; (6):53-5. PubMed ID: 9036615
    [No Abstract]   [Full Text] [Related]  

  • 15. Goserelin-induced new-onset depressive disorder.
    Kohen I; Koppel J
    Psychosomatics; 2006; 47(4):360-1. PubMed ID: 16844898
    [No Abstract]   [Full Text] [Related]  

  • 16. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
    Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
    Montgomery BS; Borwell JP; Higgins DM
    Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous manifestations of relapsing polychondritis in a patient receiving goserelin for carcinoma of the prostate.
    Labarthe MP; Bayle-Lebey P; Bazex J
    Dermatology; 1997; 195(4):391-4. PubMed ID: 9529565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
    Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
    BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goserelin.
    Nurs Times; 2006 Jan 17-23; 102(3):41. PubMed ID: 16440976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.